As of today (2024-04-16), Silk Road Medical's share price is $17.71. Silk Road Medical's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.86. Hence, Silk Road Medical's Price to Tangible Book Ratio of today is 4.59.
The historical rank and industry rank for Silk Road Medical's Price-to-Tangible-Book or its related term are showing as below:
SILK'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.18 Med: 17.56 Max: 20.06
Current: 4.59
During the past 7 years, Silk Road Medical's highest Price to Tangible Book Ratio was 20.06. The lowest was 3.18. And the median was 17.56.
SILK's Price-to-Tangible-Book is ranked worse than 69.35% of 708
companies
in the Medical Devices & Instruments industry
Industry Median: 2.615
vs SILK: 4.59
A closely related ratio is called PB Ratio. As of today, Silk Road Medical's share price is $17.71. Silk Road Medical's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.86. Hence, Silk Road Medical's P/B Ratio of today is 4.59.
Silk Road Medical Price-to-Tangible-Book Historical Data
The historical data trend for Silk Road Medical's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Silk Road Medical Annual Data
Trend
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
17.56
20.06
18.83
12.37
3.18
Silk Road Medical Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
12.37
9.61
8.11
3.81
3.18
Competitive Comparison
For the Medical Devices subindustry, Silk Road Medical's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silk Road Medical Price-to-Tangible-Book Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Silk Road Medical's Price-to-Tangible-Book falls into.
Silk Road Medical Price-to-Tangible-Book Calculation
Silk Road Medical's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Silk Road Medical Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Silk Road Medical's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Silk Road Medical (Silk Road Medical) Business Description
Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SILK has been successfully added to your 